Patent Application – Bone Marrow Damage
20.03.2020 As part of the immanent advancement of cell-based liquid biopsy, we are happy to announce the filing of the latest patent application of the SanoLibio Project introducing the discovery …
About Us
Our Story
SanoLibio is an internationally recognized biomedical technology innovator. Having understood that it is firstly technology that enables advancement, we have opened a new window with our proprietary automated cell separation platform into rare blood cell analysis which is seen as the next generation of liquid biopsy diagnostics potentially managing many health issues of our times, including cancer, myocardial infarction, diabetes and many more. Our unique rare cell enrichment platform called “Walderbach” is one of the very few worldwide to allow comprehensive ultra-rare cell enrichment and detection which is a crucial detail for the understanding of disease evolution and delineation that ultimately leads to better health care.
Our History
SanoLiBio is a German based medtech start-up focusing on the enrichment of rare cells in general and circulating tumor cells (CTCs) in particular taken from liquid biopsy. CTCs are seen as THE early stage cancer biomarkers. They are the first detectable sign of cancer in the human body at all.
Gallery
Section subtitle
Our Team
Dr. Stefan Schreier
CEO
- 10 years expertise in cell separation and diagnostic test development
- Worked at X-Zell Biotec (Thailand) as Product and Development Manager
- Co-founder of X-Zell Biotec (US), a start-up focused on early stage cancer detection
- Ph.D. in Pathobiology from Mahidol University Bangkok; M.Sc. in Bio-Engineering from University of Applied Sciences Munich, Germany; Assoc. Eng. in Communication technology from Siemens Technik Akademie Munich
Timo Peter
CCO ( Dipl.-Bioing )
- 20 years in the financial industry (Bryan, Garnier & Co, Glotec Ventures, Deutsche Bank)
- M.Sc. in Bio-Engineering from University of Applied Sciences Munich; Degree in Patent Engineering from University of Hagen
Ulrich Lang
Investor Relations Europe
- +30 years in automation of RFID products, 7 years Vice President (Automation) at Smarttrac
- Founder and General Manager of IMASYS AG, aquired by Assa Abloy in 2005
- 7 years, General Manager for Amatech Automation AG
Usa Suteelaxnaporn
CFO (SanoLibio Thailand )
- Head of Finance and investment AMQ Group, Auracollection Co., Pechet and Associates, PwC, Thailand
- Member of Federation of Accounting Professions of Thailand and Chartered Financial Analyst (CFA Level 1)
- Bachelor of Business Administration (international Program) with GPA 3.94/4.00 (First Class Honors), Chulalongkorn University
- Exchange semester at Kenan-Flagler Business School, University of North Carolina, North Carolina, USA
- Mrs. Usa is our expert in finance operations and located in Bangkok.
Dr.Suparerk Borwornpinyo
COO (SanoLibio Thailand )
- 5 years clinical study experience in stem cell and gene therapy for thalassemia with bluebird bio Inc..,BLUE(NASDAQ)
- Scientific consultant in gene and cell therapy for genetic diseases and cancers, Ramathibodi Research Center, Mahdiol University
- Founder of Excellent Center for Drug Discovery (ECDD), Mahidol University,Thailand
- Chief Operating Officer (COO) of ECDD
- Ph.D in Physiology (Biotechnolgy), North Carolina State University, Raleigh, USA
Dr.Suparerk is the networker and faciltater of the project in Thailand
Dr. Peter Frost
Business Advisor and Partner Europe
- More than 20 years experience in Sales & Marketing of Life Science products for basic and clinical research. Introduced successfully innovative Biotech companies in the European as well as US market (e.g. SpheroTec, Sirion Biotech, InSphero)
- Was involved in the market entry of StemCell´s RoboSep, a automated cell separation system
- Developed PELOBIOTECH GmbH to one of the leading cell culture companies
- Founder and CEO of PELOBIOTECH GmbH and FROST LIFESCIENCE
Dr. Frost is our consultant and partner in business development Germany/Europe and is located in Munich.